

Novel Drug Discovery Concepts and Targets within Genetic Kidney Diseases

A **nephrology-focused** pharmaceutical company is seeking **innovative drug discovery concepts and druggable targets** specifically for genetic kidney diseases, with a focus on **rare conditions**. They are also interested in novel **drug discovery platforms** that can be utilized for genetic kidney disease research.



Approaches of Interest:

- **Therapeutic targets for Alport Syndrome;** submissions should focus on either (i) small molecules, peptides, and druggable targets that can modulate COL4A3, COL4A4, and COL4A5 gene function or (ii) therapeutics targets that are critical to key pathways or pathophysiological processes, such as abnormalities in glomerular structure or renal filtration function triggered by type IV collagen mutations
- Small molecules and peptides that can directly modulate **the function of causative gene molecules** of other genetic kidney diseases such as focal segmental glomerulosclerosis, nephronophthisis, autosomal dominant polycystic kidney disease, autosomal recessive polycystic kidney disease, autosomal dominant tubulointerstitial kidney disease, cystinuria, Gitelman syndrome, nephrogenic diabetes insipidus, generalized pseudohypoaldosteronism type 1, etc
- **Systems or platforms** that can be applied to the discovery and development of new drug targets and small molecules are also of interest

Out of Scope:

- Non-genetic kidney disorders
- Interventions targeting late-stage phenotypes such as fibrosis and progression to renal failure
- Cell therapy, gene therapy, medical devices

Developmental Stages of Interest:

- Research at basic to late preclinical stages is within scope
- Ideally, the research submitted should have intervention effects in *in vivo* disease models, although *in vitro* models will still be considered

Submission Information






Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. Our client is also open to novel research proposals which can be outlined using this [submission form](#). In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.

Please check your organization's external collaboration policy and/or guidelines before submitting to this anonymous campaign, which may result in introduction and subsequent partnering discussions with the client company. Please get in touch with campaigns@inpart.io if you have any queries.

Opportunities sought

-  Technologies
-  Academics and expertise
-  Centres of excellence
-  Research projects
-  Spinout companies
-  Biotech assets

Submissions

Please submit relevant, non-confidential opportunities online [here](#)

Deadline: **20th January 2025 - 11:59 pm GMT**

Have any questions?

Contact our team at discover@in-part.co.uk

